Cargando…
Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (allo-SCT) has a curative potential for myelofibrosis (MF) patients; however, its association with a high therapy-related mortality (TRM) remains a big obstacle that needs to be overcome. Ruxolitinib (RUXO), a novel JAK1/2 inhibitor, can be used as...
Autores principales: | Sakoda, Teppei, Kanamitsu, Yoko, Mori, Yasuo, Sasaki, Kensuke, Yonemitsu, Etsuko, Nagae, Konosuke, Yoshimoto, Goichi, Kamezaki, Kenjiro, Kato, Koji, Takenaka, Katsuto, Miyamoto, Toshihiro, Furue, Masutaka, Iwasaki, Hiromi, Akashi, Koichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643178/ https://www.ncbi.nlm.nih.gov/pubmed/28824063 http://dx.doi.org/10.2169/internalmedicine.8491-16 |
Ejemplares similares
-
Recent advances in the diagnosis and management of primary myelofibrosis
por: Takenaka, Katsuto, et al.
Publicado: (2018) -
Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013) -
Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016) -
Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
por: Manduzio, Palma
Publicado: (2017) -
Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)